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ARTICLE
The Value of Molecular Haplotypes in a Family-Based Linkage
Study
E. M. Gillanders, J. V. Pearson, A. J. M. Sorant, J. M. Trent, J. R. O’Connell, and J. E. Bailey-Wilson
Novel methods that could improve the power of conventional methods of gene discovery for complex diseases should
be investigated. In a simulation study, we aimed to investigate the value of molecular haplotypes in the context of a
family-based linkage study. The term “haplotype” (or “haploid genotype”) refers to syntenic alleles inherited on a single
chromosome, and we use the term “molecular haplotype” to refer to haplotypes that have been determined directly by
use of a molecular technique such as long-range allele-speciﬁc polymerase chain reaction. In our study, we simulated
genotype and phenotype data and then compared the powers of analyzing these data under the assumptions that various
levels of information frommolecular haplotypes were available. (This information was available because of the simulation
procedure.) Several conclusions can be drawn. First, as expected, when genetic homogeneity is expected or when marker
data are complete, it is not efﬁcient to generate molecular haplotyping information. However, with levels of heterogeneity
and missing data patterns typical of complex diseases, we observed a 23%–77% relative increase in the power to detect
linkage in the presence of heterogeneity with heterogeneity LOD scores 13.0 when all individuals are molecularly hap-
lotyped (compared with the power when only standard genotypes are used). Furthermore, our simulations indicate that
most of the increase in power can be achieved by molecularly haplotyping a single individual in each family, thereby
making molecular haplotyping a valuable strategy for increasing the power of gene mapping studies of complex diseases.
Maximization of power, given an existing family set, can be particularly important for late-onset, often-fatal diseases
such as cancer, for which informative families are difﬁcult to collect.
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In contrast to simple Mendelian disorders, susceptibility
to common complex diseases such as cancer, type-2 dia-
betes, or Alzheimer disease is multifactorial and involves
multiple genetic and environmental risk factors. Efforts to
localize susceptibility genes involved in complex diseases
have been limited by genetic heterogeneity, incomplete
penetrance, phenocopies, and, frequently, late age at dis-
ease onset. Each of these factors can result in a signiﬁcant
reduction in statistical power for any individual gene-
mapping study. Thus, novel methods that could improve
the power of traditional methods of gene discovery for
complex diseases should be examined. Complex diseases
include most common diseases of adult life, and they ac-
count for most human morbidity and mortality. There-
fore, improvements in the methods used to decipher their
genetic etiologies should be of paramount importance.
Reconstruction of haplotypes has proven critical to sev-
eral studies that have succeeded in identifying genetic fac-
tors involved in complex-trait susceptibility.1–4Haplotypes
provide additional information to both linkage and link-
age disequilibrium (LD) studies and therefore may facili-
tate the mapping of a disease gene by allowing a more
precise localization of the gene within a chromosomal
region initially identiﬁed by linkage analysis. Candidate
regions for complex diseases, initially identiﬁed by ge-
nomewide linkage scans, can often be prohibitively large
(20–30 cM). These regions can contain upwards of 100
genes, which requires further narrowing of the candidate
interval before positional cloning efforts.
Recent advances in molecular technologies and the
availability of the human genome sequence have revolu-
tionized researchers’ ability to catalogue human genetic
variation. However, reconstruction of haplotypes fromcon-
ventional genotypes in diploid organisms such as humans
can be complicated, since the parental origins of the two
alleles of each genotype are not directly observable. There
are three principle haplotyping approaches: (1) statistical
estimation, (2) inference from family data, and (3) em-
pirical (or “direct”) molecular haplotyping. The reliability
of statistical methods in reconstruction of haplotypes de-
pends on the number of markers, allele frequencies, frac-
tion of missing data, genotyping error rate, and LD be-
tween markers.5–7 Inferring phase from family data can be
limited by uninformative or missing genotypes. In addi-
tion, late age at onset for many complex diseases can pre-
clude collection of DNA samples from previous genera-
tions, thereby further limiting strategies to reconstruct
haplotypes with use of family data. In contrast, molecular
haplotypingmethods are empirical and are not dependent
on statistical assumptions or estimation.
Two popular molecular haplotyping methods include
(1) long-range, allele-speciﬁc PCR (AS-PCR)8–10 and (2) dip-
loid-to-haploid methods, such as conversion.11 Crawford
and Nickerson12 describe these methods in detail. In brief,
www.ajhg.org The American Journal of Human Genetics Volume 79 September 2006 459
Figure 1. Pedigree structure used in simulation analyses. Each
pedigree was required to have three affected individuals for ascer-
tainment. Which three individuals were affected was somewhat
limited, to minimize the inclusion of families uninformative for
linkage analysis.
Figure 2. Examples of pedigrees excluded from simulations. Families were not included if the three affected members were all founders
(A), a parent-parent-offspring trio (B), a trio of parent, offspring, and a founder who is not a grandparent (C), a founder-founder-
spouse trio (D), or a trio of individuals 7, 12, and either 5 or 6 (E) (individual numbering as in ﬁg. 1).
these molecular techniques unambiguously reconstruct
haplotypes in the following manner. AS-PCR involves se-
lective PCR ampliﬁcation of one of the two chromosomes
at a given heterozygous locus. This is frequently done by
designing PCR primers that will match (or mismatch) one
allele at the 3′ end of the primer. By use of long-range PCR
methods, a molecular haplotype of up to 40 kb can be
determined. The conversion method entails generation of
mouse-human somatic cell hybrids, which retain only a
subset of human chromosomes. Once hybrids that are
monosomic for the chromosome of interest are identiﬁed,
haplotypes can be reconstructed with conventional geno-
typing of the haploid cells. In short, bothmethods provide
unequivocal molecular haplotypes. Several studies have
provided evidence of the value of molecular haplotyping
in the context of LD studies.13–15
In this study, we used simulations to compare the power
of using various levels of molecular haplotypes (available
because of the simulation procedure) with the power of
using standard genotyping in the context of a family-based
linkage study. To clarify, we are not assuming any molec-
ular haplotyping method in particular; we are simply as-
suming that we have molecularly derived haplotypes avail-
able. These results will need to be considered within the
context of considerably increased laboratory expenditure.
Current molecular haplotyping methods are fairly limited
and not particularly well suited for high-throughput work;
however, positive results might motivate new molecular or
statistical approaches that could more easily capitalize on
the beneﬁts of molecular haplotyping information.
Material and Methods
Using the Genometric Analysis Simulation Program (GASP),16 we
simulated qualitative trait and marker data for the three-gener-
ation pedigree structure shown in ﬁgure 1. The simulated qual-
itative trait was due to a single locus with an autosomal dominant
mode of inheritance and a disease allele (D) frequency equal to
0.01. Individuals with both the DD and Dd genotypes had an
80% probability of developing the disease. Of individuals with a
normal genotype (dd), 4% developed the trait. All individuals
within the pedigree were considered to be beyond the age of risk.
Families were ascertained (i.e., selected from randomly simu-
lated families to be in the analyzed sample) on the basis of having
a minimum of three affected members who were at least mini-
mally informative for linkage analysis. Speciﬁcally, families were
excluded if the three affected members were (1) all founders (ﬁg.
2A), (2) a parent-parent-offspring trio (ﬁg. 2B), (3) a parent-off-
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Figure 3. Examples of speciﬁc pedigrees included in simulation analyses
Table 1. Type I Error of Four STR FM Markers (1 cM Apart), with 0% Families Linked (H0)
Model Molecular Haplotyping Information Options for Missing Marker Data
Percentage of
1,000 Replicates
with HLOD
11.0 12.0 13.0
1 All members genotyped (P0) No marker data missing (M0) 1.8 .2 .0
2 All members genotyped (P0) Marker data missing for top generation (M1) 1.6 .1 .0
3 All members genotyped (P0) Marker data missing for top generation and 50% of middle generation (M2) 1.9 .2 .0
4 Affected individuals haplotyped (P1) No marker data missing (M0) 1.8 .2 .0
5 Affected individuals haplotyped (P1) Marker data missing for top generation (M1) 1.8 .3 .0
6 Affected individuals haplotyped (P1) Marker data missing for top generation and 50% of middle generation (M2) 1.2 .2 .0
7 All members haplotyped (P2) No marker data missing (M0) 1.8 .2 .0
8 All members haplotyped (P2) Marker data missing for top generation (M1) 1.8 .3 .0
9 All members haplotyped (P2) Marker data missing for top generation and 50% of middle generation (M2) 1.9 .1 .1
spring pair and a founder who is not a grandparent (ﬁg. 2C), (4)
a founder-founder-spouse trio (ﬁg. 2D), or (5) a trio comprising
individuals 7, 12, and either 5 or 6 (ﬁg. 2E). This ascertainment
procedure was designed to mimic the real procedures used in
linkage studies of qualitative traits. Simulations of families for
each replicate continued until there were 100 pedigrees that met
our ascertainment criteria. Examples of pedigrees included in our
simulation are shown in ﬁgure 3.
GASP was used to simulate genotype data for eight STRmarkers,
including four STR genomewide-scan (GWS) markers that were
10 cM apart and four STR ﬁne-mapping (FM) markers that were
1 cM apart. Each simulated STR marker had ﬁve equally frequent
alleles. In separate simulations, we generated genotype data for
four SNP markers. These SNP GWS markers were 1 cM apart and
had aminor-allele frequency of 0.40. The geneticmarker lociwere
all assumed to be in linkage equilibrium. Furthermore, because
the marker data were simulated, the haplotypes were knownwith
certainty for all individuals in the data set. Therefore, unlike a
real linkage study (where only the genotype at each marker is
known), we were able to write out the simulated marker data
showing which allele was maternally or paternally derived for all
loci in all individuals. This is the information that would be avail-
able if that person were molecularly haplotyped. We then in-
cluded various levels of these simulated molecular haplotypes in
the linkage analyses, as described below.
All simulations are outlined in ﬁgures 4–7. In each simulated
family, the trait could be either linked or unlinked to the analyzed
marker set. We simulated three different levels of genetic hetero-
geneity in which the percentage of linked families varied: (1)
none of the families linked to the marker set (H0), (2) 100% of
the families linked to the marker set (H1), and (3) 25% of the
families linked to the marker set (H2). The H0 level of hetero-
geneity was simulated, to conﬁrm that the inclusion ofmolecular
haplotypes did not cause increases in type I error rates. The H1
and H2 levels of heterogeneity were used to determine the extent
to which the inclusion of molecular haplotype information into
the linkage analysis improved power.
For each level of heterogeneity (H0, H1, and H2), at least nine
different models of data availability were considered (ﬁg. 4). Spe-
ciﬁcally, for each replicate, we considered three different levels
of haplotyping information: (1) no molecular haplotypes were
included in the linkage analysis (only individual genotypes were
used) (P0), (2) simulated molecular haplotypes of affected indi-
viduals were included in the linkage analysis (only genotypes of
unaffected individuals were used) (P1), and (3) simulated molec-
ular haplotypes from all genotyped individuals were included in
the linkage analysis (P2). These different levels of simulated mo-
lecular haplotyping were used to determine whether all geno-
typed persons in the pedigree needed to be molecularly haplo-
typed to increase linkage power or whether linkage power gains
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Figure 4. Outline of nine STR FM analyses for all three levels of genetic heterogeneity (H0, H1, and H2). (Results are shown in tables
1–3). For each level of genetic heterogeneity (A), we considered three levels of molecular haplotyping information (P0, P1, and P2)
(B), and, for each level of molecular haplotyping information, we considered three levels of missing data (M0, M1, and M2) (C).
Table 2. Power of Four STR FM Markers (1 cM Apart), with 100% of Families Linked (H1)
Model Molecular Haplotyping Information Options for Missing Marker Data
Percentage of 1,000
Replicates with HLOD
11.0 12.0 13.0
1 All members genotyped (P0) No marker data missing (M0) 100.0 100.0 100.0
2 All members genotyped (P0) Marker data missing for top generation (M1) 100.0 100.0 100.0
3 All members genotyped (P0) Marker data missing for top generation and 50% of middle generation (M2) 100.0 100.0 100.0
4 Affected individuals haplotyped (P1) No marker data missing (M0) 100.0 100.0 100.0
5 Affected individuals haplotyped (P1) Marker data missing for top generation (M1) 100.0 100.0 100.0
6 Affected individuals haplotyped (P1) Marker data missing for top generation and 50% of middle generation (M2) 100.0 100.0 100.0
7 All members haplotyped (P2) No marker data missing (M0) 100.0 100.0 100.0
8 All members haplotyped (P2) Marker data missing for top generation (M1) 100.0 100.0 100.0
9 All members haplotyped (P2) Marker data missing for top generation and 50% of middle generation (M2) 100.0 100.0 100.0
could be obtained by performing molecular haplotyping on a
smaller proportion of the family members.
For each level of molecular haplotyping information (P0, P1,
and P2), we considered three levels of missing marker data (i.e.,
different patterns of ungenotyped family members): (1) no miss-
ing data (marker data available for everyone) (M0), (2) marker
data missing for individuals in our top generation of our simu-
lated pedigree (individuals 1 and 2) (M1), and (3) marker data
missing for individuals in our top generation as well as for 50%
of individuals in our second generation (a randomly chosen half
of founders and a randomly chosen half of nonfounders) (M2).
We used these different missing data rates to evaluate whether
includingmolecular haplotype data in the linkage analysis always
increased power or whether it increased power only in the pres-
ence of incomplete family genotype data.Whenmarker datawere
missing for an individual, that person’s genotypes (at all marker
loci) and simulated molecular haplotype were all treated as un-
known in the linkage analysis. For each of these 27 models (nine
basic data availability combinations times three levels of genetic
heterogeneity), a set of four STR FM (1-cM spacing) markers sur-
rounding the trait locus was analyzed (ﬁg. 4).
For heterogeneity model H2 only, these four FM STR markers
were also analyzed for two more levels of haplotyping informa-
tion: simulated molecular haplotyping for one randomly chosen
member of our middle generation (P3) and simulated molecular
haplotyping for one randomly chosen member of our bottom
generation (P4), for each level of missing data (M1, M2, and M3)
(ﬁg. 5). Once again, these two levels of simulated molecular hap-
lotyping were used to determine whether all genotyped persons
in the pedigree needed to be molecularly haplotyped to increase
linkage power or whether linkage power gains could be obtained
by performing molecular haplotyping on only a small proportion
462 The American Journal of Human Genetics Volume 79 September 2006 www.ajhg.org
Table 3. Power of Four STR FM Markers (1 cM Apart), with 25% of Families Linked (H2)
Model Molecular Haplotyping Information Options for Missing Marker Data
Percentage of
1,000 Replicates
with HLOD
11.0 12.0 13.0
1 All members genotyped (P0) No marker data missing (M0) 98.6 94.5 87.0
2 All members genotyped (P0) Marker data missing for top generation (M1) 97.3 88.8 74.9
3 All members genotyped (P0) Marker data missing for top generation and 50% of middle generation (M2) 95.0 81.0 63.1
4 Affected individuals haplotyped (P1) No marker data missing (M0) 98.6 94.5 87.0
5 Affected individuals haplotyped (P1) Marker data missing for top generation (M1) 98.7 94.3 86.6
6 Affected individuals haplotyped (P1) Marker data missing for top generation and 50% of middle generation (M2) 97.5 89.3 74.4
7 All members haplotyped (P2) No marker data missing (M0) 98.6 94.5 87.0
8 All members haplotyped (P2) Marker data missing for top generation (M1) 98.7 94.6 87.0
9 All members haplotyped (P2) Marker data missing for top generation and 50% of middle generation (M2) 98.1 90.4 77.4
Table 4. Power of Four STR FM Markers (1 cM Apart), with 25% of Families Linked (H2) and with Additional Molecular
Haplotyping Levels
Model Molecular Haplotyping Information Options for Missing Marker Data
Percentage of 1,000
Replicates with HLOD
11.0 12.0 13.0
10 One individual haplotyped (middle generation) (P3) No marker data missing (M0) 98.6 94.5 87.0
11 One individual haplotyped (middle generation) (P3) Marker data missing for top generation (M1) 98.5 92.1 82.6
12 One individual haplotyped (middle generation) (P3) Marker data missing for top generation and 50% of middle generation (M2) 97.0 87.1 71.7
13 One individual haplotyped (bottom generation) (P4) No marker data missing (M0) 98.6 94.5 87.0
14 One individual haplotyped (bottom generation) (P4) Marker data missing for top generation (M1) 97.3 88.8 74.9
15 One individual haplotyped (bottom generation) (P4) Marker data missing for top generation and 50% of middle generation (M2) 94.7 81.1 62.8
of the family members. Again, for heterogeneity model H2 only
and the basic nine data-availability combinations, we also ana-
lyzed two additional marker sets: four GWS STR markers 10 cM
apart (ﬁg. 6) and four GWS SNP markers 1 cM apart (ﬁg. 7). For
each described scenario, we analyzed 1,000 replicates.
We used version 2 of the VITESSE program17,18 to performmul-
tipoint linkage analyses. VITESSE is a linkage-analysis program
that uses the Elston-Stewart algorithm to compute the likelihood
of pedigree data. VITESSE uses a novel set-recoding scheme to
reduce the number of genotypes required in the likelihood cal-
culation, thereby improving the computational performance.The
program accepts a wide variety of special input formats, including
phased genotype data. Standard genotype-input format does not
distinguish the parental source of alleles in heterozygous geno-
types. VITESSE permits a vertical bar delimiter (F) between alleles
to set the paternal source of the allele. For example, an input
genotype of 1F2 in the pedigree ﬁle is read by VITESSE as spec-
ifying the alleles 1 and 2 as paternally and maternally inherited,
respectively. Moreover, this input format can be used to specify
paternally inherited n-locus haplotypes at n loci by specifying
phased genotypes at each of the n loci. This is how our simulated
molecular haplotypes were speciﬁed in the linkage analysis. Mul-
tipoint linkage analyses were performed under the assumption
that the genetic model is the same as the generating one.
In multipoint likelihood-based linkage analysis, the likelihood
of the marker data conceptually is a sum over all possible hap-
lotype conﬁgurations, and phase information for one or more
individuals in the family reduces the number of conﬁgurations.
When VITESSE reads in molecularly determined haplotypes as
described above, a reduction in the number of possible haplotype
conﬁgurations in the family is done at the time of genotype input.
Thereafter, VITESSE performs the standard likelihood calculations
over the remaining possible haplotype conﬁgurations in the fam-
ily. It is this reduction in the uncertainty about the true haplotype
conﬁguration in the family that is expected to increase power to
detect linkage when molecular haplotypes are included in the
linkage analysis.
Heterogeneity LOD–score (HLOD) calculations to test for link-
age in the presence of genetic heterogeneitywere performedusing
the admixture test.19 Power to detect linkage (or, in the com-
pletely unlinked situation, type I error rate) was measured as the
percentage of 1,000 replicates that reached an HLOD of at least
1.0, at least 2.0, and at least 3.0.
Analyses were run on the TGen Research Institute IBM 1350
computational cluster. The cluster had 512 IBM X Series compu-
tational nodes, each with two 2.4 GHz Intel Xeon processors, for
a total of 1,024 central processing units. Each node had 2 GB of
RAM and Gigabit Ethernet network connections. The operating
system was RedHat Enterprise Linux 3.0, PBSPro was used to han-
dle job scheduling, and the IBM CSM (Cluster System Manage-
ment) was used to monitor and maintain the cluster. Of the
nodes, 128 are equipped with low-latency, high-throughput My-
rinet interconnects. These nodes also have an extra 2 GB of RAM
per node to allow for memory-intensive computations. PBSPro
manages these resources and allows jobs to be run exclusively on
these Myrinet nodes. All cluster nodes have access to a shared
parallel 1 TB ﬁle system (IBMGPFS), which allows each individual
node to read and write to the same data ﬁles simultaneously
across the cluster. The GPFS ﬁle system uses IBM FAStT SAN (stor-
age area network) storage units, providing high performance and
high reliability.
Results
Four STR FM (1-cM Spacing) Marker Analyses
Summary results for the four STR FM marker multipoint
analyses are presented in tables 1, 2, and 3 for genetic
heterogeneity models H0, H1, and H2, respectively. In all
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Figure 5. Outline of additional STR FM analyses (H2 only). For the H2 level of heterogeneity only (A), we considered two additional
levels of molecular haplotyping information (B), each with molecular haplotyping information available for a single individual. For each
of these two levels of molecular haplotyping information, we considered three levels of missing data (M0, M1, and M2) (C). Results
are shown in table 4.
simulations, models 1–3 assume no one has been molec-
ularly haplotyped (P0); thus, only genotype data were in-
cluded in the linkage analysis. Models 4–6 were analyzed
under the assumption that all genotyped affected indi-
viduals had been molecularly haplotyped (P1) (with use
of some molecular method), so that simulated molecular
haplotypes for the affected individuals as well as geno-
types for unaffected individuals were used in the analysis.
Finally, models 7–9 assume everyone has beenmolecularly
haplotyped (P2), so that simulated molecular haplotypes
were included in the analysis of all genotyped familymem-
bers. In table 4 (heterogeneitymodel H2 only), haplotyping
schemes P3 and P4 (one family member molecularly hap-
lotyped) are presented. In these models (10–15) the simu-
latedmolecular haplotype for one individual andgenotypes
for the remaining familymemberswere used in theanalysis.
For each phase information level, threemissingmarkerdata
options (M0, M1, and M2) were considered.
Table 1 presents a summary of HLOD results for the
replicates in which none of the simulated families have
their trait locus linked to the markers tested (H0). In this
situation, any linkage detected was a type I error. The
HLOD results across different molecular haplotyping and
missing marker–data options were similar and close to ex-
pected values. For each model, !2% of HLODs were 11.0.
Less than 0.5% of HLODs were 12.0, and only a single
replicate had an HLOD 13.0.
Table 2 presents a summary of HLODs when 100% of
the ascertained families are linked to the simulatedmarker
set (H1) and the same four tightly spaced markers are in-
cluded in the multipoint analyses. All 1,000 replicates, for
each of the nine different data availability models, had
LOD (data not shown) and HLODs 13.0.
Table 3 gives a summary of HLODs when 25% of the
families are linked to the simulated marker set (H2) and
the same four STR FM markers are included in the multi-
point analyses. When no one was missing (either geno-
types or haplotypes) marker data (M0) (models 1, 4, and
7), there was no difference in results across levels of mo-
lecular haplotyping information included in the linkage
analysis. When our top generation (individuals 1 and 2)
was missing marker data (M1) (models 2, 4, and 8), there
was a small relative increase in power to detect linkage
with HLODS 11.0, 12.0, and 13.0 when direct haplotyping
information was available for everyone (relative increases
of 1%, 7%, and 16%, respectively). Missing marker–data
pattern M2 (models 3, 6, and 9) assumes marker data are
missing for founders in our top generation as well as for
50% of individuals in our middle generation. With this
level of missing data, there was a larger increase in power
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Figure 6. Outline of additional STR GWS analyses (H2 only). For the H2 level of heterogeneity only, we also analyzed four STR markers
at GWS density (markers 10 cM apart). Results are shown in table 5.
to detect HLODs 11.0, 12.0, and 13.0 when all individuals
are haplotyped (relative increases of 3%, 12%, and 23%,
respectively).
When all individuals were haplotyped (P2), the power
was only slightly greater than when only the affected in-
dividuals were haplotyped (P1). For example, with the
more-extreme missing data pattern (M2), the power to
detect linkage with HLODs 13.0 increased notably from
63.1% when individuals are genotyped (P0) (model 3) to
74.4% when molecular haplotypes from affected individ-
uals were included in the linkage analysis (P1) (model 6)
but only slightly more, to 77.0%, when everyone’s mo-
lecular haplotypeswere included in the analysis (P2) (model
9). In these simulated pedigrees, having molecular hap-
lotyping information for everyone (compared with only
for affected individuals) translates into determining mo-
lecular haplotype information for up to 13 additional un-
affected individuals (ﬁg. 3).When only one individualwas
haplotyped (table 4), the power to detect linkage with
HLODs 13.0 increased from 63.1% when only individuals
were genotyped to 71.7% when the single molecularly
haplotyped individual was in our middle generation (P3)
(model 3 in table 3, compared with model 12 in table 4).
In contrast, if the molecularly haplotyped individual was
in our bottom generation (P4), then the power was vir-
tually the same as when only individuals were genotyped,
for all HLOD criteria considered (model 3 in table 3 com-
pared with model 15 in table 4).
Four STR GWS (10 cM Apart) Marker Analyses
Table 5 summarizes power results for multipoint analyses
of a four STRmarker set with GWS spacing for simulations
in which 25% of the families are linked to the simulated
marker set (H2). With a less dense set of STR markers,
power was lower for all options considered than with the
FM marker set (as expected), but incorporation of molec-
ular haplotypes into the linkage analysis provided a small
relative increase in the power to detect linkage with an
HLOD of 3.0, even when no marker data were missing.
When some marker data were missing, the improvement
in power with the inclusion of molecular haplotypes was
more striking, especially when HLOD was 13.0. For the
M1 and M2 missing-data patterns, the relative increase
was 22% and 43%, respectively, in the power with HLODs
13.0 (models 8 and 9). Again, most of the increase in
power was gained by including the simulated molecular
haplotypes from only the affected individuals.
Four SNP GWS (1 cM Apart) Marker Analyses
Table 6 provides a summary of the results of analyses of
four SNP GWS markers when ∼25% of the families were
linked to the simulated trait (H2). With use of less infor-
mative SNP markers, there was again a small increase in
the power to detect linkage with an HLOD of 3.0 even
when no marker data were missing and molecular hap-
lotype information was incorporated. When marker data
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Figure 7. Outline of additional SNP GWS analyses (H2 only). For the H2 level of heterogeneity only, we also analyzed four SNP markers
at GWS density (markers 1 cM apart). Results are shown in table 6.
were missing, there was a substantial increase in the power
to detect linkage with an HLOD 13.0 when simulatedmo-
lecular haplotypes for all nonmissing individuals were
used in the analysis, compared with when only genotypes
were used. When marker data were missing only for our
top generation (M1), the power to detect linkage with an
HLOD 13.0 increased 33%when simulatedmolecular hap-
lotyping information for all nonmissing individuals was
used in the analysis (model 8). When marker data were
missing for our top generation and 50% of our middle
generation (M2), power with anHLOD 13.0 increased 77%
when simulated molecular haplotypes on all individuals
were included in the analysis (model 9).
Discussion
Efforts to localize susceptibility genes involved in complex
diseases such as cancer have been hindered by genetic
heterogeneity, incomplete penetrance, phenocopies, and
variable age at disease onset. Each of these factors results
in a substantial loss of statistical power for any gene-map-
ping study. The goal of the present study was to explore
the application of molecular haplotyping to linkage stud-
ies and the concomitant effects on power and type I error
in a family-based linkage study. Haplotype reconstruction
can increase the information available for linkage and LD
studies, thus improving their power to identify genetic fac-
tors involved in complex disease susceptibility.
However, computational methods of reconstructinghap-
lotypes can be limited as the number of markers increases
or LD between markers decreases.20,21 Haplotype inference
from family data can be limited by uninformative or miss-
ing genotypes, particularly when the age at disease onset
is late. Furthermore, most software packages used to infer
haplotypes from pedigree data (such as GENEHUNTER22
and SIMWALK223) assume linkage equilibrium among
markers, which may not be appropriate for tightly spaced
markers.24 In the current study, we used simulations to
compare the power of using direct molecular haplotyping,
to allow inclusion ofmolecular haplotypes in linkage anal-
ysis, with that obtained when only standard genotyping
is available in the context of a family-based FM linkage
study.
We used GASP to simulate a qualitative trait andmarker
data for extended pedigrees. Our intention was to make
this simulated qualitative trait representative of a complex
disease. In this regard, disease penetrance was modeled
as incomplete, and there was a high rate of phenocopies,
which is typical of complex diseases such as melanoma
or prostate cancer. In addition, we also simulated three
different levels of genetic heterogeneity. Finally, we con-
sidered three different levels of missing-marker data, the
last of which could be considered typical of a disease of
late onset age.
We evaluated the effect of both (1) increased phase in-
formation due to inclusion of molecularly determined
haplotypes in the linkage analysis and (2) decreased in-
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Table 5. Power of Four STR GWS Markers (10 cM Apart), with 25% of Families Linked (H2)
Model Molecular Haplotyping Information Options for Missing Marker Data
Percentage of
1,000 Replicates
with HLOD
11.0 12.0 13.0
1 All members genotyped (P0) No marker data missing (M0) 98.3 92.8 81.9
2 All members genotyped (P0) Marker data missing for top generation (M1) 96.0 84.4 67.3
3 All members genotyped (P0) Marker data missing for top generation and 50% of middle generation (M2) 91.3 73.5 50.2
4 Affected individuals haplotyped (P1) No marker data missing (M0) 98.5 93.0 83.0
5 Affected individuals haplotyped (P1) Marker data missing for top generation (M1) 98.3 92.1 81.9
6 Affected individuals haplotyped (P1) Marker data missing for top generation and 50% of middle generation (M2) 95.0 84.8 68.2
7 All members haplotyped (P2) No marker data missing (M0) 98.6 93.3 82.9
8 All members haplotyped (P2) Marker data missing for top generation (M1) 98.5 92.6 81.8
9 All members haplotyped (P2) Marker data missing for top generation and 50% of middle generation (M2) 96.4 86.4 71.8
formation due to missing data on the type I error rate by
simulating 1,000 replicates with the qualitative trait un-
linked to the marker loci in 100% of ascertained families
(H0). Table 1 shows the results of analysis of four STR FM
markers for nine molecular haplotype and missing data
scenarios. We conclude that the incorporation of molec-
ular haplotyping information does not increase the type
I error rate in an extended-pedigree FM linkage study. As
we expected, results were similar across the various levels
of molecular haplotyping information included in the
linkage analysis. In addition, our results show that, in ex-
tended pedigrees, missing marker data also do not appear
to inﬂate the type I error rate.We considered three different
missing marker data patterns, including one in which ge-
notypes or haplotypes were missing for founders in our
top generation as well as for 50% of individuals in our
middle generation. This level of missing data is charac-
teristic of complex disorders with late onset age, because
parents of affected individuals are frequently deceased.
Table 1 shows no increase in the type I error rate with
increasing missing-marker data.
When the simulated qualitative trait was linked to the
simulated marker loci in all pedigrees (i.e., when there was
linkage homogeneity) (H1) and four STR FMmarkers were
included in the multipoint analyses, power to detect link-
age was complete. In all such simulated data sets, regard-
less of the amount of molecular haplotyping information
available or the level of missing-marker data, each repli-
cate had LOD scores (not shown) and HLODs 13.0 (table
2). Given the extremely high level of power when there
is no genetic heterogeneity, it is not surprising that the
presence or absence of molecular haplotyping informa-
tion had no effect on these results. This genetic homo-
geneity would be more characteristic of a simple Men-
delian disorder than of a complex disease. As expected,
this would not be the type of study that would beneﬁt
from the incorporation of molecular haplotyping infor-
mation. Thus, for simple Mendelian disorders, one could
not justify the increased cost of molecular haplotyping
methodologies.
Finally, we simulated the situation in which 25% of the
families were linked to the simulated marker set. First, we
included four highly informative, closely spaced (1 cM
apart) FM STR markers in our analyses and saw that, in
the absence of missing-marker data, there is no beneﬁt in
including molecular haplotyping information. However,
for a more realistic missing-data pattern for a complex
disease (M1 or M2), inclusion of directly measured mo-
lecular haplotypes can increase the power to detect linkage
with an HLOD of 3.0 by as much as 23% (table 3). Of
course, these results must be balanced against the increased
cost of molecular haplotypingmethodologies. Becausemo-
lecular haplotyping of everyone would be prohibitively ex-
pensive, we also considered intermediate schemes in which
only certain individuals would be haplotyped. All of our
simulations show that most of the improvement in power
gained by incorporating molecular haplotyping informa-
tion can be captured simply by directly haplotyping a
small number of individuals. Speciﬁcally, we can capture
60% of this increase in power simply by molecular hap-
lotyping a carefully selected single individual (table 4).
Continuing with this level of genetic heterogeneity (25%
of families linked), which is more characteristic of a com-
plex disease, we also analyzed a set of STR markers at a
GWS density of 10 cM apart. As expected, the value of
molecular haplotypes is even greater with a less dense set
of markers (table 5). With missing-data patterns typical of
a complex disease, there was a 22%–43% relative increase
in the power to detect linkage with an HLOD 13.0. In the
absence of a biologically relevant candidate gene, many
gene-mapping studies of complex diseases begin with a
global GWS for linkage. Our results show that the in-
corporation of molecular haplotyping information can
substantially increase the power of these studies. Current
trends for genomewide linkage studies favor genotyping
thousands of SNP markers instead of hundreds of STR
markers. Our simulations suggest that the value of direct
haplotyping information may be even greater in such
SNP-based studies, particularly for diseases with late onset,
when substantial marker data will be missing (table 6).
With substantial missing-marker data, the power to detect
linkage with an HLOD 13.0 increased by 77% with the
incorporation of haplotype information. Several studies
have now reported an increase in linkage power with use
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Table 6. Power of Four SNP GWS Markers (1 cM Apart), with 25% Families Linked (H2)
Model Molecular Haplotyping Information Options for Missing Marker Data
Percentage of
1,000 Replicates
with HLOD
11.0 12.0 13.0
1 All members genotyped (P0) No marker data missing (M0) 97.0 88.0 71.6
2 All members genotyped (P0) Marker data missing for top generation (M1) 92.9 73.8 55.3
3 All members genotyped (P0) Marker data missing for top generation and 50% of middle generation (M2) 82.2 57.7 35.2
4 Affected individuals haplotyped (P1) No marker data missing (M0) 97.1 89.4 74.2
5 Affected individuals haplotyped (P1) Marker data missing for top generation (M1) 96.7 87.1 71.2
6 Affected individuals haplotyped (P1) Marker data missing for top generation and 50% of middle generation (M2) 92.0 75.4 55.1
7 All members haplotyped (P2) No marker data missing (M0) 97.5 90.0 75.2
8 All members haplotyped (P2) Marker data missing for top generation (M1) 97.3 89.2 73.5
9 All members haplotyped (P2) Marker data missing for top generation and 50% of middle generation (M2) 94.5 79.4 62.4
of a high-density map of SNP markers compared with a
less dense25–29 set of STR markers. However, most labora-
tories today are using a twofold more dense SNP map (1
SNP every 0.5 cM) than the one simulated in this study;
therefore, it is inappropriate to use these data to compare
the power of using STR versus SNP markers in a GWS.
It should be noted that our analyses with VITESSE ver-
sion 2 assume not only a molecular haplotype but also a
parental source for each haplotype. Although there are a
priori two possible parental sources for each molecular
haplotype, parental phase can be established with a single
informative transmission, because the parental source of
a single allele identiﬁes the parental source of all alleles
on the haplotype. With a sufﬁciently dense set of poly-
morphic markers, we believe it is reasonable to assume that
parental phase can be established in an individual. Using
this knowledge of phase and a sufﬁciently dense set of
polymorphic markers to identify regions shared identical
by descent (IBD) from the same parent, we can assume
that the parental source is also known in the individual’s
siblings. If the parents are not genotyped, then parental
source cannot be determined, but it can be arbitrarily as-
sumed, provided both parents have the same phenotype.
However, in practice, if untyped parents have different
phenotypes or if two siblings share no alleles IBD along
the chromosome, then it may be necessary to consider an-
alyses for both possible parental phases.
Complex diseases account for most of the public health
burden. Characterization of the genetic factors involved
in disease etiology has proven beneﬁcial in the diagnosis,
prognosis, and treatment of disease. However, efforts to
understandmolecular pathogeneses of these diseases have
been limited. This study provides further evidence of the
increased value of molecular haplotyping in the context
of linkage studies. However, it must be balanced against
the considerable cost and effort of molecular haplotyping
methodologies. At today’s costs, these methods would be
economically feasible only to follow up a few regions of
suggestive linkage when collection of additional families
is difﬁcult. However, these positive results should encour-
age novel molecular techniques, which could facilitate the
use of molecular haplotyping information. In particular,
maximizing power given an existing family set can be
particularly important in late-onset, often-fatal traits such
as pancreatic or lung cancer, for which informative fam-
ilies are difﬁcult to collect.
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